BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

8124

532331

AJANTPHARM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

AJANTA PHARMA LIMITED performance

Today’s low

Today’s high

₹ 2752.40 ₹ 2801.40
₹ 2770.90

52 week low

52 week high

₹ 2111.05 ₹ 3485.00
₹ 2770.90

Open Price

₹ 2791.50

Prev. Close

₹ 2775.20

Volume (Shares)

19769.00

Total traded value

₹ 547.77

Upper Circuit

₹ 3330.20

Lower Circuit

₹ 2220.20

info

AJANTA PHARMA LIMITED Share Price Update

As of the latest trading session, AJANTA PHARMA LIMITED share price is currently at ₹ 2767.3, which is down by ₹ -7.89 from its previous closing. Today, the stock has fluctuated between ₹ 2752.40 and ₹ 2801.40. Over the past year, AJANTA PHARMA LIMITED has achieved a return of 25.42 %. In the last month alone, the return has been 5.80 %. Read More...

AJANTA PHARMA LIMITED fundamentals


  • Market cap (Cr)

    34,844.36

  • P/E Ratio (TTM)

    39.13

  • Beta

    0.65

  • Book Value / share

    282.55

  • Return on equity

    24.24%

  • EPS (TTM)

    70.94

  • Dividend yield

    1.86%

  • Net profit/quarter (Cr)

    252.45

info icon alternate text
  • Market cap (Cr)

    34,872.06

  • P/E Ratio (TTM)

    39.13

  • Beta

    0.60

  • Book Value / share

    282.55

  • Return on equity

    24.24%

  • EPS (TTM)

    70.94

  • Dividend yield

    1.86%

  • Net profit/quarter (Cr)

    252.45

info icon alternate text

AJANTA PHARMA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1101.92
Operating Expense 803.00
Net Profit 252.45
Net Profit Margin (%) 22.91
Earnings Per Share (EPS) 20.16
EBITDA 369.56
Effective Tax Rate (%) 23.99
Particulars SEP 2024 (Values in Cr)
Revenue 1128.91
Operating Expense 860.05
Net Profit 234.98
Net Profit Margin (%) 20.81
Earnings Per Share (EPS) 18.75
EBITDA 343.25
Effective Tax Rate (%) 24.00
Particulars JUN 2024 (Values in Cr)
Revenue 1077.27
Operating Expense 795.08
Net Profit 236.03
Net Profit Margin (%) 21.91
Earnings Per Share (EPS) 18.77
EBITDA 344.20
Effective Tax Rate (%) 23.99
Particulars MAR 2024 (Values in Cr)
Revenue 926.07
Operating Expense 733.81
Net Profit 162.69
Net Profit Margin (%) 17.56
Earnings Per Share (EPS) 12.92
EBITDA 260.83
Effective Tax Rate (%) 27.99
Particulars DEC 2023 (Values in Cr)
Revenue 1085.29
Operating Expense 793.88
Net Profit 220.15
Net Profit Margin (%) 20.28
Earnings Per Share (EPS) 17.48
EBITDA 340.90
Effective Tax Rate (%) 27.85
Particulars MAR 2024 (Values in Cr)
Revenue 3971.12
Operating Expense 2990.65
Net Profit 807.24
Net Profit Margin (%) 20.32
Earnings Per Share (EPS) 64.11
EBITDA 1235.91
Effective Tax Rate (%) 26.41
Particulars MAR 2023 (Values in Cr)
Revenue 3411.27
Operating Expense 2844.17
Net Profit 558.72
Net Profit Margin (%) 16.37
Earnings Per Share (EPS) 43.61
EBITDA 832.03
Effective Tax Rate (%) 20.16
Particulars MAR 2022 (Values in Cr)
Revenue 3140.64
Operating Expense 2379.83
Net Profit 719.86
Net Profit Margin (%) 22.92
Earnings Per Share (EPS) 55.52
EBITDA 1030.62
Effective Tax Rate (%) 20.06
Particulars MAR 2021 (Values in Cr)
Revenue 2718.59
Operating Expense 1920.07
Net Profit 675.64
Net Profit Margin (%) 24.85
Earnings Per Share (EPS) 77.59
EBITDA 1020.48
Effective Tax Rate (%) 25.10
Particulars MAR 2020 (Values in Cr)
Revenue 2196.42
Operating Expense 1764.03
Net Profit 441.13
Net Profit Margin (%) 20.08
Earnings Per Share (EPS) 50.55
EBITDA 713.06
Effective Tax Rate (%) 27.99
Particulars MAR 2024 (Values in Cr)
Book Value / Share 282.34
ROE % 23.47
ROCE % 31.59
Total Debt to Total Equity 0.01
EBITDA Margin 29.86
Particulars MAR 2023 (Values in Cr)
Book Value / Share 268.14
ROE % 17.68
ROCE % 22.21
Total Debt to Total Equity 0.01
EBITDA Margin 23.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 380.24
ROE % 22.77
ROCE % 28.91
Total Debt to Total Equity 0.01
EBITDA Margin 31.28
Particulars MAR 2021 (Values in Cr)
Book Value / Share 344.52
ROE % 23.38
ROCE % 31.64
Total Debt to Total Equity 0.02
EBITDA Margin 35.46
Particulars MAR 2020 (Values in Cr)
Book Value / Share 296.34
ROE % 19.31
ROCE % 27.10
Total Debt to Total Equity 0.02
EBITDA Margin 29.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 270.17
ROE % 24.24
ROCE % 32.49
Total Debt to Total Equity 0.01
EBITDA Margin 31.12
Particulars MAR 2023 (Values in Cr)
Book Value / Share 256.94
ROE % 17.42
ROCE % 21.63
Total Debt to Total Equity 0.01
EBITDA Margin 24.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 369.15
ROE % 23.78
ROCE % 29.60
Total Debt to Total Equity 0.01
EBITDA Margin 32.82
Particulars MAR 2021 (Values in Cr)
Book Value / Share 331.80
ROE % 25.28
ROCE % 33.43
Total Debt to Total Equity 0.01
EBITDA Margin 37.54
Particulars MAR 2020 (Values in Cr)
Book Value / Share 280.65
ROE % 19.17
ROCE % 26.68
Total Debt to Total Equity 0.01
EBITDA Margin 32.46
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 130.77
Total Assets 4638.39
Total Liabilities 4638.39
Total Equity 3567.36
Share Outstanding 125914655
Price to Book Ratio 8.28
Return on Assets (%) 17.59
Return on Capital (%) 22.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 330.90
Total Assets 4679.02
Total Liabilities 4679.02
Total Equity 3387.99
Share Outstanding 125914655
Price to Book Ratio 4.71
Return on Assets (%) 12.56
Return on Capital (%) 17.35
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 211.79
Total Assets 4055.58
Total Liabilities 4055.58
Total Equity 3264.34
Share Outstanding 85415770
Price to Book Ratio 4.90
Return on Assets (%) 17.57
Return on Capital (%) 21.82
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 209.61
Total Assets 3778.72
Total Liabilities 3778.72
Total Equity 2995.63
Share Outstanding 86531770
Price to Book Ratio 5.40
Return on Assets (%) 17.30
Return on Capital (%) 21.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.25
Total Assets 3318.69
Total Liabilities 3318.69
Total Equity 2598.87
Share Outstanding 87261270
Price to Book Ratio 4.87
Return on Assets (%) 14.09
Return on Capital (%) 17.7
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 63.06
Total Assets 4217.44
Total Liabilities 4217.44
Total Equity 3413.57
Share Outstanding 125914655
Price to Book Ratio 8.28
Return on Assets (%) 19.14
Return on Capital (%) 23.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 269.92
Total Assets 4304.79
Total Liabilities 4304.79
Total Equity 3246.45
Share Outstanding 125914655
Price to Book Ratio 4.71
Return on Assets (%) 12.97
Return on Capital (%) 17.21
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 145.25
Total Assets 3780.49
Total Liabilities 3780.49
Total Equity 3169.18
Share Outstanding 85415770
Price to Book Ratio 4.90
Return on Assets (%) 19.04
Return on Capital (%) 22.71
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 151.98
Total Assets 3532.06
Total Liabilities 3532.06
Total Equity 2884.98
Share Outstanding 86531770
Price to Book Ratio 5.40
Return on Assets (%) 19.12
Return on Capital (%) 23.42
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 87.85
Total Assets 3049.15
Total Liabilities 3049.15
Total Equity 2461.30
Share Outstanding 87261270
Price to Book Ratio 4.87
Return on Assets (%) 14.46
Return on Capital (%) 17.92
Particulars MAR 2024 (Values in Cr)
Net Income 1113.93
Cash from Operations 1097.20
Cash from Investing 65.39
Cash from Financing -1051.06
Net change in Cash -200.60
Free Cash Flow 1249.61
Particulars MAR 2023 (Values in Cr)
Net Income 745.25
Cash from Operations 943.40
Cash from Investing -559.60
Cash from Financing -108.20
Net change in Cash 124.31
Free Cash Flow 1117.88
Particulars MAR 2022 (Values in Cr)
Net Income 909.48
Cash from Operations 800.84
Cash from Investing -74.10
Cash from Financing -459.71
Net change in Cash 27.90
Free Cash Flow 949.68
Particulars MAR 2021 (Values in Cr)
Net Income 900.18
Cash from Operations 806.70
Cash from Investing -282.38
Cash from Financing -318.29
Net change in Cash -24.36
Free Cash Flow 978.31
Particulars MAR 2020 (Values in Cr)
Net Income 663.97
Cash from Operations 611.60
Cash from Investing -224.40
Cash from Financing -128.63
Net change in Cash 103.74
Free Cash Flow 851.02
Particulars MAR 2024 (Values in Cr)
Net Income 1096.95
Cash from Operations 987.63
Cash from Investing 105.02
Cash from Financing -1047.70
Net change in Cash -207.33
Free Cash Flow 1140.20
Particulars MAR 2023 (Values in Cr)
Net Income 699.85
Cash from Operations 861.85
Cash from Investing -501.31
Cash from Financing -105.12
Net change in Cash 129.86
Free Cash Flow 1037.51
Particulars MAR 2022 (Values in Cr)
Net Income 900.54
Cash from Operations 735.81
Cash from Investing -66.04
Cash from Financing -457.30
Net change in Cash 19.00
Free Cash Flow 882.33
Particulars MAR 2021 (Values in Cr)
Net Income 902.09
Cash from Operations 664.90
Cash from Investing -162.68
Cash from Financing -268.90
Net change in Cash 35.41
Free Cash Flow 831.87
Particulars MAR 2020 (Values in Cr)
Net Income 612.67
Cash from Operations 439.41
Cash from Investing -115.91
Cash from Financing -134.00
Net change in Cash 50.97
Free Cash Flow 675.78
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.56 20.19 2.05 287.83 34.11 / 77.70
BLISS GVS PHARMA LTD 121.70 15.95 1.26 1282.36 92.25 / 184.95
CIPLA LTD 1554.40 25.16 4.42 125536.01 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 277.60 23.00 2.81 817.00 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.56 22.63 6.38 287.83 34.11 / 77.70
AMRUTAJAN HEALTH LTD 666.35 39.06 6.46 1926.46 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8839.60 131.84 32.52 22099.00 5000.00 / 9199.00
BLISS GVS PHARMA LTD 121.70 15.81 1.25 1282.36 92.25 / 184.95

AJANTA PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2772.50 -0.09 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 2722.30
  • 26 Days 2643.10
  • 10 Days 2685.60
  • 50 Days 2652.40
  • 12 Days 2675.30
  • 100 Days 2706.90
  • 20 Days 2650.90
  • 200 Days 2684.70
2723.30 PIVOT

First Support

2617.20

First Resistance

2782.10

Second Support

2558.40

Second Resistance

2888.20

Third Support

2452.30

Third Resistance

2947.00

RSI

59.26

ADX

21.92

MACD

32.17

Williams % R

-10.79

Commodity Channel Index (CCI)

109.20

Date

2025-04-28

Week

43343.00

Same Day

74804.00

Month

46088.00

1 Year

0.65

3 Year

0.40

Over 1 Month

5.80%

down

Over 1 Year

25.42%

down

Over 3 Months

8.04%

down

Over 3 Years

33.76%

down

Over 6 Months

-5.04%

down

Over 5 Years

22.73%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

AJANTA PHARMA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
7.39%
Promoter Holdings
66.25%
FII
8.86%
DII
17.48%
Promoter Shares(Pledge Percentage)
12.61%
Name Shares Category
Yogesh M Agrawal, Trustee Yogesh Agrawal Trust 1.8078147E7 (14.47%) Shareholding of Promoter and Promoter Group
Rajesh M Agrawal, Trustee Rajesh Agrawal Trust 1.8078148E7 (14.47%) Shareholding of Promoter and Promoter Group
Ravi P Agrawal, Trustee Ravi Agrawal Trust 1.6242904E7 (13.0%) Shareholding of Promoter and Promoter Group
Aayush M Agrawal, Trustee Aayush Agrawal Trust 1.4112924E7 (11.3%) Shareholding of Promoter and Promoter Group
Gabs Investments Pvt Ltd 1.2588393E7 (10.08%) Shareholding of Promoter and Promoter Group
Uti-flexi Cap Fund 3700328.0 (2.96%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 3549053.0 (2.84%) Public Shareholding
Ganga Exports Being Represented By Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal 3348261.0 (2.68%) Shareholding of Promoter and Promoter Group
Kotak Small Cap Fund 1828677.0 (1.46%) Public Shareholding
Canara Robeco Mutual Fund A/c Canara Robeco Emerging Equities 1729000.0 (1.38%) Public Shareholding
Hdfc Large And Mid Cap Fund 1563389.0 (1.25%) Public Shareholding
Tata Aia Life Insurance Co Ltd-whole Life Mid Cap Equity Fund-ulif 009 04/01/07 Wle 110 1556565.0 (1.25%) Public Shareholding
Ravi P Agrawal 285000.0 (0.23%) Shareholding of Promoter and Promoter Group
Aayush M Agrawal 30000.0 (0.02%) Shareholding of Promoter and Promoter Group
Mannalal B. Agrawal 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

AJANTA PHARMA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Feb 2024 26.0 Interim 2 08 Feb 2024 Equity shares
04 Aug 2023 15.0 Special 04 Aug 2023 Equity shares
04 Aug 2023 10.0 Interim 1 04 Aug 2023 Equity shares
11 Nov 2022 7.0 Interim 14 Nov 2022 Equity shares
09 Nov 2021 9.5 Interim 10 Nov 2021 Equity shares
12 Nov 2020 9.5 Interim 13 Nov 2020 Equity shares
15 Nov 2019 13.0 Interim 18 Nov 2019 Equity shares
09 Nov 2018 9.0 Interim 12 Nov 2018 Equity shares
23 Mar 2017 7.0 Interim 2 25 Mar 2017 Equity shares
07 Nov 2016 6.0 Interim 08 Nov 2016 Equity shares
17 Mar 2016 8.0 Interim 19 Mar 2016 Equity shares
25 Jun 2015 6.0 Final 27 Jun 2015 Equity shares
24 Jul 2014 10.0 Final 28 Jul 2014 Equity shares
18 Jul 2013 6.25 Final 22 Jul 2013 Equity shares
28 Jun 2012 7.5 Final 02 Jul 2012 Equity shares
23 Jun 2011 5.0 Final 25 Jun 2011 Equity shares
29 Jun 2010 3.5 Final 01 Jul 2010 Equity shares
30 Jun 2009 2.5 Final 03 Jul 2009 Equity shares
27 Jun 2008 2.5 Final 01 Jul 2008 Equity shares
19 Sep 2007 2.0 Final 21 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
23 Jun 2022 22 Jun 2022 1:2
18 Sep 2013 17 Sep 2013 1:2
Ex-Date Old FV NEW FV Record Date
20 Mar 2015 5.0 2.0 23 Mar 2015
09 Aug 2012 10.0 5.0 10 Aug 2012
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Feb 2024 26.0 Interim 2 08 Feb 2024 Equity shares
04 Aug 2023 15.0 Special 04 Aug 2023 Equity shares
04 Aug 2023 10.0 Interim 1 04 Aug 2023 Equity shares
11 Nov 2022 7.0 Interim 14 Nov 2022 Equity shares
09 Nov 2021 9.5 Interim 10 Nov 2021 Equity shares
12 Nov 2020 9.5 Interim 13 Nov 2020 Equity shares
15 Nov 2019 13.0 Interim 18 Nov 2019 Equity shares
09 Nov 2018 9.0 Interim 12 Nov 2018 Equity shares
23 Mar 2017 7.0 Interim 2 25 Mar 2017 Equity shares
07 Nov 2016 6.0 Interim 08 Nov 2016 Equity shares
17 Mar 2016 8.0 Interim 19 Mar 2016 Equity shares
25 Jun 2015 6.0 Final 27 Jun 2015 Equity shares
24 Jul 2014 10.0 Final 28 Jul 2014 Equity shares
18 Jul 2013 6.25 Final 22 Jul 2013 Equity shares
28 Jun 2012 7.5 Final 02 Jul 2012 Equity shares
23 Jun 2011 5.0 Final 25 Jun 2011 Equity shares
29 Jun 2010 3.5 Final 01 Jul 2010 Equity shares
30 Jun 2009 2.5 Final 03 Jul 2009 Equity shares
27 Jun 2008 2.5 Final 01 Jul 2008 Equity shares
19 Sep 2007 2.0 Final 21 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
23 Jun 2022 22 Jun 2022 1:2
18 Sep 2013 17 Sep 2013 1:2
Ex-Date Old FV NEW FV Record Date
20 Mar 2015 5.0 2.0 23 Mar 2015
09 Aug 2012 10.0 5.0 10 Aug 2012

AJANTA PHARMA LIMITED Share Price

Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market.

The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.

In branded generic business in emerging markets in Asia and Africa, Ajanta Pharma's products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The company's institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.

Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been successfully approved by US FDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Its R&D centre has a team of over 750 scientists working on innovative products for various markets across the globe.

Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up its 1stManufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period from 1995 to 1998, the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its Paithan manufacturing facility in 2008.

In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. During the year, the company bought a manufacturing facility at Chitegaon in Aurangabad, Maharashtra to fuel the company's growth. Also during the year, Ajanta Pharma became the first generic company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug.

In 2010, Ajanta Pharma entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc. In 2011, Ajanta Pharma emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.

In 2012, Ajanta Pharma was ranked among the Top 10 pharma companies in Franco Africa. During the year 2013, Ajanta Pharma commenced sales to the US market. In 2014, the company set up its 2nd dedicated R&D centre at Kandivli in Mumbai for India and emerging markets. During the year, the company inaugurated a new facility in Dahej, Bharuch, Gujarat for catering to the requirements of markets like USA, WHO and emerging markets.

In 2015, the company announced the launch of Montelukast Sodium Oral Granules. The company also announced the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market.

In 2017, the company inaugurated and commissioned 1st phase at a new facility in Guwahati, Assam. The company's Dahej, Gujarat facility was approved by the USFDA without any observation in April 2017.

On 11 July 2017, Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma (APL) informed the company that promoters have sold 27 lakh equity shares in APL, representing about 3.07% of APL's equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% in APL. This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.

On 9 February 2018, Ajanta Pharma announced that its formulation facility at Dahej in Gujarat was inspected by USFDA from 5 to 9 February 2018. At the end of the inspection, no Form 483 was issued to the company by the USFDA.

As on 31 March 2018,the company has six subsidiaries overseas, including one step down subsidiary under its roof.

The company's capex investment in manufacturing facilities and R&D which has taken the total from Rs 997 crore in FY 2017 to Rs 1,225 crore in FY 2018.

The Company had convened Extra-Ordinary General Meeting on 10th October 2017 as per the directions of National Company Law Tribunal for obtaining consent of shareholders for merger of 'Gabs Investments Private Ltd. ' with the Company.

During the FY2019, company's wholly owned subsidiary viz., Ajanta Pharma UK Limited was dissolved on 18th December 2018. Post that, the company has five operating subsidiaries overseas, including one step down subsidiary.

The total capex for FY 2019 was Rs 361 crore and propose to spend further Rs 350 crore in FY 2020, mainly on Guwahati, Pithampur and corporate office in Mumbai.

in March 2019, the Company bought back 7,69,230 (Seven lakhs sixty-nine thousand two hundred and thirty only) fully paidup equity shares of the face value of Rs 2/- each at a price of Rs 1300 per share for an aggregate amount of Rs 100 crore.

The Scheme of Amalgamation and Arrangement of Gabs Investments Pvt. Ltd. with the Company which was filed by the Company with National Company Law Tribunal (NCLT) in the last year, was rejected by NCLT on grounds cited in its order. The Company had preferred an appeal before the National Company Law Appellate Tribunal (NCLAT) challenging the order of NCLT. However, after considering all the pros and cons at length, it was deemed appropriate to withdraw the appeal. Accordingly, the same was withdrawn on 7th December 2018.

During the FY2020, third phase of Guwahati plant, new manufacturing facility in Pithampur, Madhya Pradesh and new R & D building in Kandivli, Mumbai were completed and became fully functional. Expansion of facility at Dahej has been commenced and the same is expected to be over by December 2020. During the year, an amount of Rs 245 crore was incurred on capex.

The Board of Directors have approved buyback proposal on 3 November 2020, for purchase by the Company of up to 7,35,000 shares of Rs 2 each (representing 0.84% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of Rs 1,850 per equity share for an aggregate amount not exceeding Rs 135.98 crore in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018.

During the quarter ended 31 December 2020,the group had bought back its 735000 equity shares of Rs 2/-each at Rs 1850 per share for an aggregate amount of Rs 135.98 crore and extinguished those shares on 30 December 2020.

The Company launched 16 new products in FY 2022, including four 1st to market products in the country. During the year 2022, it launched 3 new products and filed 8 ANDAs. It received 2 final and 1 tentative approval. There are 20 ANDAs awaiting approval from US FDA.

The Company launched 23 new products in FY 2023 with six first-to-market products.

Parent organization Indian Private
NSE symbol AJANTPHARM
Founded 1979
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Ajanta Pharma Ltd?

Answer Field

The share price of Ajanta Pharma Ltd for NSE is ₹ 2767.3 and for BSE is ₹ 2769.5.

What is the Market Cap of Ajanta Pharma Ltd?

Answer Field

The market cap of Ajanta Pharma Ltd for NSE is ₹ 3,48,44.36 Cr. and for BSE is ₹ 3,48,72.06 Cr. as of now.

What is the 52 Week High and Low of Ajanta Pharma Ltd?

Answer Field

The 52 Week High and Low of Ajanta Pharma Ltd for NSE is ₹ 3485.00 and ₹ 2111.05 and for BSE is ₹ 3485.75 and ₹ 2022.05.

How to Buy Ajanta Pharma Ltd share?

Answer Field

You can trade in Ajanta Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Ajanta Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 25.42%.

What is the Current Share Price of Ajanta Pharma Ltd?

Answer Field

Ajanta Pharma Ltd share price is for NSE ₹ 2767.3 & for BSE ₹ 2769.5 as on Apr 29 2025 12:09 PM.

What is the Market Cap of Ajanta Pharma Ltd Share?

Answer Field

The market cap of Ajanta Pharma Ltd for NSE ₹ 3,48,44.36 & for BSE ₹ 3,48,72.06 as on Apr 29 2025 12:09 PM.

What is the P/E Ratio of Ajanta Pharma Ltd Share?

Answer Field

As on Apr 29 2025 12:09 PM the price-to-earnings (PE) ratio for Ajanta Pharma Ltd share is 39.13.

What is the PB ratio of Ajanta Pharma Ltd Share?

Answer Field

As on Apr 29 2025 12:09 PM, the price-to-book (PB) ratio for Ajanta Pharma Ltd share is 282.55.

How to Buy Ajanta Pharma Ltd Share?

Answer Field

You can trade in Ajanta Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ajanta Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Ajanta Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ajanta Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|